DAX25.382 -0,1%Est506.024 +0,1%MSCI World4.343 -0,1%Top 10 Crypto12,35 +1,5%Nas23.734 +0,3%Bitcoin79.234 +1,4%Euro1,1670 ±0,0%Öl64,76 +0,7%Gold4.590 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA RENK RENK73 Siemens Energy ENER6Y Allianz 840400 Lufthansa 823212 Amazon 906866 Infineon 623100 BASF BASF11 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX wenig verändert -- Asiens Börsen letztlich uneins - Nikkei knackt Rekord -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- Zalando, Munich Re, DroneShield, Nordex, UBS im Fokus
Top News
Munich Re-Aktie tiefer: Naturkatastrophenschäden 2025 erneut bei über 100 Milliarden US-Dollar Munich Re-Aktie tiefer: Naturkatastrophenschäden 2025 erneut bei über 100 Milliarden US-Dollar
TSMC weitet US-Investitionen auf 165 Mrd. Dollar aus – Teil eines Deals zu Trump-Zöllen TSMC weitet US-Investitionen auf 165 Mrd. Dollar aus – Teil eines Deals zu Trump-Zöllen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ipsen Aktie

Kaufen
Verkaufen
Ipsen Aktien-Sparplan
129,40 EUR +0,10 EUR +0,08 %
STU
120,40 CHF +0,46 CHF +0,38 %
BRX
Ipsen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.10,54 Mrd. EUR

KGV26,49Div. Rendite1,26%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0ESMG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0010259150

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIPSEF

Ipsen Aktien News

DatumMeistgelesen
GlobeNewswireLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
GlobeNewswireIpsen – Half year statement – 2023 12 31
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireCapital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
GlobeNewswireIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023
GlobeNewswireResults from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
PR NewswireIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
PR NewswireIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
PR NewswireIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
PR NewswireIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023
GlobeNewswireIpsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
GlobeNewswireIPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023
GlobeNewswireIpsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2023
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2023
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2023
GlobeNewswireIpsen updates on QM-1114 regulatory process
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2023
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2023
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2023
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2023
GlobeNewswireIpsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswireIpsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2023
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2023
GlobeNewswireExelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
GlobeNewswireUS FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2023
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2023
GlobeNewswireIpsen S.A. publishes its 2023 Half-Year Financial Report
GlobeNewswireIpsen delivers solid H1 2023 results and upgrades its full-year guidance

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.